BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 31917969)

  • 1. Optimization and qualification of a functional anti-drug antibody assay for HIV-1 bnAbs.
    Seaman MS; Bilska M; Ghantous F; Eaton A; LaBranche CC; Greene K; Gao H; Weiner JA; Ackerman ME; Garber DA; Rosenberg YJ; Sarzotti-Kelsoe M; Montefiori DC
    J Immunol Methods; 2020 Apr; 479():112736. PubMed ID: 31917969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies.
    Bharadwaj P; Riekofski C; Lin S; Seaman MS; Garber DA; Montefiori D; Sarzotti-Kelsoe M; Ackerman ME; Weiner JA
    J Immunol Methods; 2020 Apr; 479():112764. PubMed ID: 32070674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission.
    van Dorsten RT; Reh L; Trkola A; Morris L; Moore PL
    J Virol; 2022 Feb; 96(4):e0193421. PubMed ID: 34935437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.
    Sherpa C; Le Grice SFJ
    Curr HIV Res; 2020; 18(2):114-131. PubMed ID: 32039686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Antibodies for HIV-1 Prevention.
    Walsh SR; Seaman MS
    Front Immunol; 2021; 12():712122. PubMed ID: 34354713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention.
    Thavarajah JJ; Hønge BL; Wejse CM
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
    Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
    Front Immunol; 2021; 12():697683. PubMed ID: 34354709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives.
    Mahomed S
    Clin Microbiol Rev; 2024 Jun; 37(2):e0015222. PubMed ID: 38687039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly Neutralizing Antibodies for HIV Prevention.
    Karuna ST; Corey L
    Annu Rev Med; 2020 Jan; 71():329-346. PubMed ID: 31986089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and immunogenicity of broadly neutralizing HIV monoclonal antibodies in macaques.
    Rosenberg Y; Sack M; Montefiori D; Labranche C; Lewis M; Urban L; Mao L; Fischer R; Jiang X
    PLoS One; 2015; 10(3):e0120451. PubMed ID: 25807114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
    Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibodies targeting HIV: Progress and challenges.
    Paneerselvam N; Khan A; Lawson BR
    Clin Immunol; 2023 Dec; 257():109809. PubMed ID: 37852345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broadly Neutralizing Antibodies against HIV: Back to Blood.
    Dashti A; DeVico AL; Lewis GK; Sajadi MM
    Trends Mol Med; 2019 Mar; 25(3):228-240. PubMed ID: 30792120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinal effect of HIV-1 antibody therapy.
    Naranjo-Gomez M; Pelegrin M
    Curr Opin HIV AIDS; 2019 Jul; 14(4):325-333. PubMed ID: 30973419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
    Hsu DC; Mellors JW; Vasan S
    Front Immunol; 2021; 12():710044. PubMed ID: 34322136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
    Zhang Y; Chapman JH; Ulcay A; Sutton RE
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Drug Antibodies in Pigtailed Macaques Receiving HIV Broadly Neutralising Antibody PGT121.
    Lee WS; Reynaldi A; Amarasena T; Davenport MP; Parsons MS; Kent SJ
    Front Immunol; 2021; 12():749891. PubMed ID: 34867979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.